Dimension Therapeutics Inc. (NASDAQ:DMTX) Receives $16.33 Average PT from Analysts
Shares of Dimension Therapeutics Inc. (NASDAQ:DMTX) have been given an average recommendation of “Buy” by the nine research firms that are covering the stock. Three equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $16.33.
Several research firms recently weighed in on DMTX. Jefferies Group restated a “buy” rating on shares of Dimension Therapeutics in a research note on Friday, August 5th. Zacks Investment Research downgraded Dimension Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Canaccord Genuity set a $20.00 price target on Dimension Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 11th. Chardan Capital set a $10.00 price target on Dimension Therapeutics and gave the stock a “hold” rating in a research note on Sunday, August 21st. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Dimension Therapeutics in a research note on Wednesday, June 22nd.
Shares of Dimension Therapeutics (NASDAQ:DMTX) opened at 7.76 on Friday. Dimension Therapeutics has a 52 week low of $5.39 and a 52 week high of $15.55. The firm has a 50 day moving average price of $7.57 and a 200 day moving average price of $7.49. The company’s market capitalization is $194.23 million.
Dimension Therapeutics (NASDAQ:DMTX) last announced its earnings results on Thursday, August 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.06. Dimension Therapeutics had a negative return on equity of 66.58% and a negative net margin of 459.47%. Equities analysts forecast that Dimension Therapeutics will post ($1.91) EPS for the current year.
A number of hedge funds have recently modified their holdings of the stock. Teachers Advisors Inc. increased its stake in shares of Dimension Therapeutics by 224.3% in the second quarter. Teachers Advisors Inc. now owns 19,204 shares of the company’s stock valued at $115,000 after buying an additional 13,283 shares in the last quarter. TFS Capital LLC purchased a new position in Dimension Therapeutics during the second quarter worth about $220,000. FIL Ltd purchased a new position in Dimension Therapeutics during the second quarter worth about $10,133,000. BlackRock Institutional Trust Company N.A. increased its position in Dimension Therapeutics by 180.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 81,876 shares of the company’s stock worth $491,000 after buying an additional 52,724 shares during the period. Finally, BlackRock Fund Advisors increased its position in Dimension Therapeutics by 119.2% in the second quarter. BlackRock Fund Advisors now owns 317,232 shares of the company’s stock worth $1,903,000 after buying an additional 172,495 shares during the period. Institutional investors and hedge funds own 85.80% of the company’s stock.
About Dimension Therapeutics
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Stock Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related stocks with our FREE daily email newsletter.